Manufacturing innovation to drive down cell therapy costs

Minsoo Khang,Smruthi Suryaprakash,Megan Kotrappa,Widya Mulyasasmita,Shana Topp,John Wu
DOI: https://doi.org/10.1016/j.tibtech.2023.04.006
Abstract:Chimeric antigen receptor T cells (CAR-T) have demonstrated their potential to revolutionize cancer treatment. However, manufacturing remains a challenge. Multiple manufacturing innovations [e.g., vector and gene engineering, process improvements, hardware innovation, digital innovation, and point-of-care (POC) manufacturing] have the potential to help realize the full potential of CAR-T therapies.
What problem does this paper attempt to address?